Study

EORTC-40084-22084

A phase II-R and a phase III trial evaluating both *Erlotinib (PH II-R) and chemoradiation (PH III) as adjuvant treatment for patients with resected head of pancreas adenocarcinoma *(PH II-R Erlotinib randomization completed, arm 2 closed to accrual effective 04/02/14)

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 14-May-2013
Date Step1 close: 09-Jun-2015

Data management at EORTC

No

Design

Phase 3
Randomized open label

Targeted Sample size

EORTC Groups: 300 - All Groups: 950

EudraCT

2011-000618-20